SG10201912756XA - Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy - Google Patents
Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapyInfo
- Publication number
- SG10201912756XA SG10201912756XA SG10201912756XA SG10201912756XA SG10201912756XA SG 10201912756X A SG10201912756X A SG 10201912756XA SG 10201912756X A SG10201912756X A SG 10201912756XA SG 10201912756X A SG10201912756X A SG 10201912756XA SG 10201912756X A SG10201912756X A SG 10201912756XA
- Authority
- SG
- Singapore
- Prior art keywords
- patients
- treatment
- lipid lowering
- familial hypercholesterolemia
- lowering therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300393P | 2016-02-26 | 2016-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912756XA true SG10201912756XA (en) | 2020-02-27 |
Family
ID=59685647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912756XA SG10201912756XA (en) | 2016-02-26 | 2017-02-27 | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy |
| SG11201806894PA SG11201806894PA (en) | 2016-02-26 | 2017-02-27 | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806894PA SG11201806894PA (en) | 2016-02-26 | 2017-02-27 | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3419614A4 (en) |
| JP (1) | JP2019506423A (en) |
| KR (1) | KR20180115722A (en) |
| CN (1) | CN108697677A (en) |
| AU (1) | AU2017224230A1 (en) |
| BR (1) | BR112018067967A2 (en) |
| CA (1) | CA3014919A1 (en) |
| HK (1) | HK1257556A1 (en) |
| IL (1) | IL261117A (en) |
| MX (1) | MX2018010096A (en) |
| PH (1) | PH12018501790A1 (en) |
| RU (1) | RU2018133690A (en) |
| SG (2) | SG10201912756XA (en) |
| WO (1) | WO2017147598A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200253877A1 (en) * | 2018-10-18 | 2020-08-13 | Neurobo Pharmaceuticals, Inc. | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| AU2019389048A1 (en) * | 2018-11-30 | 2021-06-17 | Hdl Therapeutics, Inc | Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis |
| CN112138008B (en) * | 2020-09-30 | 2022-06-17 | 郑州大学 | Application of lomitapide in preparation of antitumor drugs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030105154A1 (en) * | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| CA2679608A1 (en) * | 2006-03-22 | 2007-10-04 | President And Fellows Of Harvard College | Methods and compositions for treating hypercholesterolemia and atherosclerosis |
| CA2861643C (en) * | 2012-01-06 | 2020-10-06 | Charles L. Bisgaier | Methods of reducing risk of cardiovascular disease |
-
2017
- 2017-02-27 WO PCT/US2017/019750 patent/WO2017147598A1/en active Application Filing
- 2017-02-27 KR KR1020187025732A patent/KR20180115722A/en unknown
- 2017-02-27 CA CA3014919A patent/CA3014919A1/en not_active Abandoned
- 2017-02-27 EP EP17757427.4A patent/EP3419614A4/en not_active Withdrawn
- 2017-02-27 SG SG10201912756XA patent/SG10201912756XA/en unknown
- 2017-02-27 MX MX2018010096A patent/MX2018010096A/en unknown
- 2017-02-27 JP JP2018544191A patent/JP2019506423A/en active Pending
- 2017-02-27 CN CN201780012667.5A patent/CN108697677A/en active Pending
- 2017-02-27 AU AU2017224230A patent/AU2017224230A1/en not_active Abandoned
- 2017-02-27 RU RU2018133690A patent/RU2018133690A/en not_active Application Discontinuation
- 2017-02-27 BR BR112018067967A patent/BR112018067967A2/en not_active Application Discontinuation
- 2017-02-27 SG SG11201806894PA patent/SG11201806894PA/en unknown
-
2018
- 2018-08-12 IL IL261117A patent/IL261117A/en unknown
- 2018-08-23 PH PH12018501790A patent/PH12018501790A1/en unknown
- 2018-12-24 HK HK18116517.0A patent/HK1257556A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180115722A (en) | 2018-10-23 |
| RU2018133690A3 (en) | 2020-05-29 |
| AU2017224230A1 (en) | 2018-08-30 |
| CA3014919A1 (en) | 2017-08-31 |
| IL261117A (en) | 2018-10-31 |
| EP3419614A4 (en) | 2019-10-09 |
| WO2017147598A1 (en) | 2017-08-31 |
| JP2019506423A (en) | 2019-03-07 |
| PH12018501790A1 (en) | 2019-06-17 |
| CN108697677A (en) | 2018-10-23 |
| RU2018133690A (en) | 2020-03-26 |
| HK1257556A1 (en) | 2019-10-25 |
| SG11201806894PA (en) | 2018-09-27 |
| BR112018067967A2 (en) | 2019-01-15 |
| EP3419614A1 (en) | 2019-01-02 |
| MX2018010096A (en) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190117T1 (en) | Mrna therapy for the treatment of ocular diseases | |
| IL260383B (en) | Low dose therapeutic treatment | |
| EP3541287A4 (en) | Radiation therapy patient platform | |
| HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
| IL276398A (en) | Combination therapy for the treatment of mastocytosis | |
| EP3212233A4 (en) | Combination therapy for treatment of disease | |
| HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
| IL262591A (en) | Methods for treating patients with familial hypercholesterolemia | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| PL3169353T3 (en) | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) | |
| HK1257556A1 (en) | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy | |
| IL264589A (en) | Combination therapy for the treatment of pancreatic cancer | |
| PL3129483T3 (en) | Combination therapy for the treatment of autoimmune diseases | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| EP3310396A4 (en) | Therapeutic nanofiber hydrogels for local treatment of brain-related diseases | |
| IL267044A (en) | Photodynamic therapeutic compounds and photodynamic methods of treatment | |
| IL253642A0 (en) | Combination therapy for the treatment of cancer | |
| IL250080A0 (en) | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) | |
| AU2017902160A0 (en) | New Therapeutic Treatment Combination | |
| AU2016902139A0 (en) | New Therapeutic Treatment Combination | |
| AU2016905000A0 (en) | Photodynamic therapeutic compounds and photodynamic methods of treatment | |
| GB201413533D0 (en) | Combination therapy for treating disorders of the vestibular system |